1 **Full title:**

2 Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand:
3 Results from a Multicenter Observational Study

4

5 **Authors:**

6 Pinyo Rattanaumpawan¹; Supunnee Jirajariyavej²; Kanokorn Lerdlamyong³; Nattawan
7 Palavutitotai⁴; Jatuporn Saiyarin⁵

8

9 **Affiliations:**

10 ¹Division of Infectious Diseases and Tropical Medicine, Department of Medicine,
11 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand

12 ²Internal Medicine Unit, Taksin Hospital, Bangkok, Thailand

13 ³Internal Medicine Unit, Vachira Phuket Hospital, Phuket, Thailand

14 ⁴Internal Medicine Unit, Lerdsin Hospital, Bangkok, Thailand

15 ⁵Internal Medicine Unit, Central Hospital, Bangkok, Thailand

16

17 **Correspondence to:**

18 Pinyo Rattanaumpawan, MD, MSCE, PhD

19 2 Wanglang Road, Bangkoknoi,

20 Bangkok 10700, Thailand

21 Tel: (+66) 2-419-7784; Fax: (+66) 2-419-7783

22 E-mail: pinyo.rat@mahidol.ac.th

23

24 **Running title:** Favipiravir Therapy for COVID-19

25

26 **Keywords:** COVID-19, Favipiravir, Pneumonia

27

28 **Abstract word count:** 245

29

30 **Manuscript word count:** 2408

31

32 **Tables:** 3

33

34 **Figure:** 1

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 SYNOPSIS

52 **Background.** Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity
53 against SARS-CoV-2. Presently, data on the effectiveness and optimal dosage of favipiravir
54 for treating COVID-19 is limited.

55 **Methods.** We conducted a retrospective observational study of hospitalized adult patients
56 with COVID-19 at five tertiary care hospitals in Thailand. We reviewed patient charts to
57 obtain all necessary data.

58 **Results.** Among 247 COVID-19 patients, 63 (23.0%) received ≥ 1 dose of favipiravir. Of
59 these, 27.0% required an O₂-nasal cannula, 9.5% required non-invasive ventilation and/or
60 high-flow O₂-therapy, and 6.4% required invasive mechanical ventilation and/or ECMO. The
61 median baseline NEWS2 score was 5(0–16). The Day-7 clinical improvement rate [95%CI]
62 was 66.7%[53.7–78.0%] in all patients, 92.5%[75.7%–99.1%] in patients who did not require
63 O₂-supplementation, and 47.2%[0.4%–64.5%] in patients who required O₂-supplementation.
64 No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%.
65 Multivariate analysis revealed three poor prognostic factors for Day-7 clinical improvement
66 [odds ratio (95%CI); *p*-value]: older age [0.94 (0.89–0.99); *p*=0.04], higher baseline NEWS2
67 score [0.64 (0.47–0.88); *p*=0.006], and lower favipiravir loading dose (≤ 45 mg/kg/day) [0.04
68 (0.005–0.4); *p*=0.006].

69 **Conclusions.** Our study reports the promising effectiveness of favipiravir for treating
70 COVID-19 patients. In addition to older age and a high baseline NEWS2 score, a low loading
71 dose of favipiravir (≤ 45 mg/kg/day) was also identified as a poor prognostic factor for early
72 clinical improvement. Further studies to explore the optimal dose and the optimal timing of
73 drug initiation for favipiravir should be performed.

74

75

76 INTRODUCTION

77 As of 16-Jun-2020, a total of 7,941,791 COVID-19 cases with 434,796 deaths have been
78 reported globally.¹ This pandemic disease is caused by a novel coronavirus, named severe
79 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a single-stranded
80 RNA beta-coronavirus encoding an RNA-dependent RNA polymerase (RdRp) and proteases.
81 Both RdRp and viral proteases are considered important targets for potentially therapeutic
82 agents. Hundreds of clinical studies are actively investigating a variety of promising agents
83 (e.g., remdesivir, favipiravir, lopinavir, hydroxychloroquine, and interferon-alpha)²; however,
84 data on the efficacy of these potentially therapeutic agents are still limited.

85 Favipiravir, a purine nucleic acid analog, is a broad-spectrum oral antiviral agent that
86 inhibits the *RdRp* of RNA viruses.³ This agent shows in vitro activity against many RNA
87 viruses, including arenaviruses, bunyaviruses, flaviviruses, Ebola virus, and influenza virus,
88 as well as SARS-CoV-2.^{4,5} Currently, two registered clinical studies of favipiravir among
89 COVID-19 patients have already reported their results.⁶ The first study
90 (ChiCTR2000029600) was a small, open-label, nonrandomized control study of 80 patients
91 with COVID-19 conducted to compare the efficacy of favipiravir plus aerosolized interferon-
92 alpha with that of lopinavir/ritonavir plus aerosolized interferon-alpha. In that study, the
93 favipiravir group showed a significantly shorter time to viral clearance and a significantly
94 higher improvement rate in chest imaging, after adjustment for potential confounders.⁷ The
95 second study (ChiCTR200030254) was a randomized control trial (RCT) of 240 patients with
96 COVID-19 pneumonia. That study, currently available as a preprint on MedRxIV, reported a
97 significantly higher clinical recovery rate on Day 7 in the favipiravir group compared with
98 the arbidol group (71.43% vs. 55.86%; $p = 0.02$).⁸

99 In February 2020, favipiravir was made available for use in Thailand under
100 emergency procurement by the Department of Disease Control of Thailand. In early March

2020, Thailand national clinical practice guidelines (CPG) for COVID-19 management recommended the initiation of favipiravir therapy in only patients with severe COVID-19 pneumonia (pneumonia with required high-flow O₂-supplementation, non-invasive mechanical ventilation, or invasive mechanical ventilation to maintain a patient O₂-saturation of 90% or more). In early May 2020, the national CPG were revised, and favipiravir is now also recommended for the treatment of mild pneumonia (i.e., abnormal chest-x-ray without desaturation). The benefits of early favipiravir initiation in mild COVID-19 cases are in need of further investigation.

The standard dose of favipiravir for treating influenza infection is 1600 mg twice daily on Day 1, followed by 600 mg twice daily on Days 2–5.⁹ A maximal loading dose of 3000 mg twice daily on Day 1 and a maintenance dose of 1200 mg twice daily on Days 2–9 were safely used in a previous Ebola study.¹⁰ Given that the optimal dose of favipiravir for treating COVID-19 is still uncertain, the Thailand national CPG recommend a fixed loading dose of 1600 mg twice daily on Day 1, followed by 600 mg twice daily on Days 2–10. A higher loading dose (60 mg/kg/day, MKD) and maintenance dose (20 MKD) are recommended in patients with a body mass index (BMI) of ≥ 35 .

Presently, data on the effectiveness and optimal dosage of favipiravir for treating COVID-19 is limited. Therefore, we conducted a retrospective study to explore these issues.

MATERIALS AND METHODS

Study Design

We conducted a retrospective observational study of COVID-19 patients who were hospitalized at any of five tertiary care hospitals in Thailand (i.e., Siriraj, Taksin, Vachira Phuket, Lerdsin, and Central hospitals) during 1 January – 30 April 2020. The study protocol

was approved with a waiver of informed consent by the institutional review boards of all involved hospitals.

Inclusion and Exclusion Criteria

We enrolled all hospitalized patients aged at least 18 years who had reverse transcription PCR-confirmed SARS-CoV-2 based on a respiratory specimen (nasopharyngeal, oropharyngeal, sputum, endotracheal aspirate, or bronchoalveolar lavage sample) and received at least one dose of favipiravir. Patients who expired or were discharged from the hospital within 24 hours after hospitalization were excluded.

Data Collection and Study Definition

We reviewed patient charts to obtain all necessary data, including demographic data, clinical data, laboratory data, and the hospital stay length. We also recorded the daily National Early Warning Score 2 (NEWS2 score). Details regarding the NEWS2 score have been published elsewhere.¹¹ The primary outcome was the rate of clinical improvement within seven days of favipiravir therapy (Day-7 clinical improvement), and the secondary outcomes were the Day-14 and Day-28 clinical improvement rates.

Clinical improvement was defined as a one-point reduction in baseline status (on the first day of favipiravir therapy) on a six-point disease severity scale at the time of evaluation. The six-point disease severity scale was categorized as follows: 6-death; 5-hospitalization for extracorporeal membrane oxygenation (ECMO) or mechanical ventilation; 4-hospitalization for non-invasive ventilation or high-flow O₂-therapy; 3-hospitalization for supplemental O₂; 2-hospitalization without the need for O₂-supplementation but requiring ongoing medical care; and 1-discharge or normalization of all vital signs and saturation of peripheral O₂ of >94% on room air for at least 24 hours.

Statistical Analysis

Categorical variables are summarized by frequency and percentage, whereas continuous variables are summarized by the median and range. Univariate analyses were performed using the Fisher-exact test for categorical data. The Mann-Whitney U test was used for continuous data. To identify the factors independently associated with the Day-7 clinical improvement, we performed a subsequent multivariate analysis including all potentially significant variables with a p -value of ≤ 0.20 in a stepwise fashion.

For all calculations, a two-tailed p -value of < 0.05 was considered statistically significant. All calculations were performed using STATA version 14.1 (Stata Corp, College Station TX).

RESULTS

During the study period, there were a total of 274 COVID-19 patients hospitalized in the participating hospitals, of which 63 patients (23.0%) received favipiravir. The baseline demographics and characteristics of all patients are listed in Table 1.

The median age of favipiravir-treated COVID-19 patients was 48 (22–85) years, and 39 of these patients (61.9%) were male. Most patients had fever (87.3%), sore throat (69.8%), or cough (74.6%) as the clinical presentation. The median duration between the symptom onset and the admission date was 6 (0–28) days, while the median duration between the symptom onset and the first day of favipiravir therapy was 8 (0–28) days.

At baseline (Day 1 of favipiravir therapy), 17 patients (27.0%) required O₂-supplementation via nasal cannula, 6 patients (9.5%) required non-invasive ventilation and/or high-flow O₂-therapy, and 4 patients (6.4%) required invasive mechanical ventilation and/or ECMO, while the remainder did not required O₂-supplementation. The median baseline NEWS2 score was 5 (0–16).

The median loading dose of favipiravir was 47.4 (29.1–71.1) MKD, and one-third of enrolled patients (33.3%) received a loading dose of ≤ 45 MKD. The median maintenance dose of favipiravir was 17.9 (10.9–26.7) MKD, and 76.2% of the subjects received a maintenance dose of ≤ 15 MKD. The median duration of favipiravir therapy was 12 (2–17) days. Within two days of initiating favipiravir treatment, nearly all patients were prescribed a chloroquine-based agent (98.4%) and a protease inhibitor (96.8%); half of them also received azithromycin (49.2%). Only a few patients received a steroid (12.7%) or tocilizumab (6.4%) at this time.

Hospital Course and Treatment Outcomes

Details regarding the hospital course and treatment outcomes are shown in Table 2. The Day-7, Day-14, and Day-28 clinical improvement rates, stratified by the requirement for O₂-supplementation are depicted in Figure 1. The Day-7 clinical improvement rate [95% CI] was 66.7% [53.7–78.0%] in all patients, 92.5% [75.7–99.1%] in patients who did not require O₂-supplementation (a six-point disease severity scale score of 1–2), and 47.2% [0.4–64.5%] in patients who required O₂-supplementation (a six-point severity scale score of 3–5). The Day-14 clinical improvement rates for all patients, those who did not require O₂-supplementation, and those who required O₂-supplementation were 85.7% [74.6%–93.2%], 100.0% [87.2%–1.00%], and 75.0% [57.8%–87.9%], respectively. Nearly all patients who required O₂-supplementation (96.1%) had clinical improvement within 28 days.

Of the 63 favipiravir-treated patients, four patients required invasive mechanical ventilation or ECMO on Day 1 of therapy, and four more cases subsequently required invasive mechanical ventilation (two cases on Day 6 and two cases on Day 9 of therapy). The 14-day, 28-day, and in-hospital mortality rates were 1.6%, 4.8%, and 7.9%, respectively. The major cause of death was superimposed infection.

The most common adverse event was diarrhea (54.0%), follow by nausea/vomit (7.9%), hepatitis (6.4%), and QT interval prolongation in EKG (6.4%). None of these adverse events were life-threatening.

Factors Associated with Day-7 Clinical Improvement

To determine the factors associated with Day-7 clinical improvement, we compared patients with Day-7 clinical improvement (cases) with patients without Day-7 clinical improvement (controls). The characteristics of both groups are shown Table 1. The cases had a significantly lower age (47 vs. 59 years; $p = 0.02$), a significantly lower BMI (25.0 vs. 27.9; $p = 0.04$), a significantly lower baseline NEWS2 score (4 vs. 5; $p = 0.003$), and a significantly lower baseline six-point disease severity scale score (2 vs. 3; $p < 0.001$). Additionally, the baseline white blood cell count was significantly lower in the case group (5420 vs. 6810; $p = 0.03$). Although the median loading and maintenance doses of favipiravir were not statistically different between these groups, the proportion of patients in the control group who received a lower loading dose of favipiravir (≤ 45 MKD) trended higher compared with the case group (26.2% vs. 47.6%; $p < 0.10$).

Table 3 shows the results of multivariate analysis. A multivariate analysis revealed three factors that were negatively associated with Day-7 clinical improvement [odds ratio (95%CI); p -value]: older age [0.94 (0.89–0.99); $p = 0.04$], higher baseline NEWS2 score [0.64 (0.47–0.88); $p = 0.006$], and a lower prescribed loading dose of favipiravir (≤ 45 MKD) [0.04 (0.005–0.4); $p = 0.006$].

DISCUSSION

The Day-7 clinical improvement rate from our study was 67.7%, which is slightly lower than the Day-7 clinical recovery rate from the abovementioned RCT of favipiravir (71.4%).⁸ However, there were a few differences between these two studies. First, the definition of

clinical recovery used in the abovementioned RCT was based mainly on clinical symptoms (e.g., fever, cough), whereas the definition of clinical improvement used in our study was based on improvement in oxygenation status. Our study included sicker patients with a higher proportion of patients who required mechanical ventilation (6.4%) as compared with the subjects of the unpublished RCT (0.9%). These differences may explain the slightly lower rate of favorable clinical responses observed in the present study.

Among the COVID-19 patients who did not require O₂-supplementation, nearly all patients (92.6%) had clinical improvement within the first seven days of favipiravir therapy. However, only half of the patients who required O₂-supplementation (47.2%) had clinical improvement within the first seven days of therapy. The rate of clinical improvement in these patients finally reached 75% on Day 14 and 83.3% on Day 28. Of the eight patients who required invasive mechanical ventilation or ECMO during their hospitalization, one patient died within the first 14 days. Therefore, the calculated 14-day mortality among this group was 12.5%. This number is similar to the 14-day mortality reported by a preliminary remdesivir RCT, in which 13 (10.4%) out of 125 patients who required mechanical ventilation or ECMO died.¹² Based on these findings, the effectiveness of favipiravir for treating COVID-19 is promising, but this drug can be slow acting in more severe cases.

Our study identified older age and a higher baseline NEWS2 scale as poor prognostic factors for early clinical response. These findings are compatible with the results from many previous publications.¹³⁻¹⁵ We also explored other baseline variables (e.g., BMI, comorbidities); however the impact of those factors disappeared after the data were adjusted by the baseline NEWS2 scale.

Given that the optimal dose of favipiravir is still uncertain, we carefully explored the association between favipiravir dosage and patient outcome. Our study confirmed that a loading dose of favipiravir of ≤ 45 MKD was a poor prognostic factor for early clinical

response. Therefore, a fixed favipiravir loading dose of 1600 mg twice daily for all patients with a BMI of <35 may be suboptimal for patients with a BMI of <35 but a body weight of ≥ 70 kg. Some might argue that this significant association may be a reflection of patients' obesity, which was also known as a poor prognostic factor in COVID-19. However, our study did not find any association between the patient's baseline BMI or body weight and the treatment outcome in the multivariate analysis.

Our study has several strengths. First, this study was a very early study to explore the effectiveness of favipiravir in active clinical cases of COVID-19. Second, this study included patients with differing disease severities; the patients ranged from mild pneumonia cases who did not require O₂-supplementation to patients with life-threatening pneumonia who required mechanical ventilation or ECMO. This diverse subject pool allowed us to thoroughly explore the effectiveness of favipiravir and the clinical course of COVID-19 disease in various degrees of severity. Lastly, the daily NEWS2 scores and six-point disease severity scale scores were carefully collected and analyzed. Consequently, we can report nearly all important clinical outcomes and compare our findings with those of other clinical trials.^{7, 8, 12}

Our study also has some limitations. First, the retrospective design resulted in a significant amount of missing data, especially for laboratory values. To resolve this issue, when performing the multivariate analysis, missing data was replaced by the mean value of a given variable. Second, majority of our patients also received chloroquine-based agent and protease inhibitors. Therefore, the good treatment response among our patients may be the synergistic results of triple combination of favipiravir, chloroquine-based agent and protease inhibitors. Furthermore, a high rate (54.0%) of diarrhea of the patients having favipiravir was probably related to protease inhibitor rather than favipiravir. Third, a sample size of 63 patients with COVID-19 pneumonia is not large enough to detect other associated factors with a low prevalence. Lastly, the generalizability of our findings may be an issue. Given that

the study was conducted in tertiary care hospitals in Thailand, results may not be applicable to primary or secondary care settings or to COVID-19 patients in other countries.

In conclusion, our study reports the promising effectiveness of favipiravir for treating COVID-19 patients in a tertiary care hospital setting. No life-threatening adverse events were identified. In addition to older age and a high baseline NEWS2 score, a low loading dose of favipiravir (≤ 45 MKD) was also identified as a poor prognostic factor for early clinical improvement. Further studies to explore the optimal dose and the optimal timing of drug initiation for favipiravir should be performed.

Notes.

Acknowledgments. The authors gratefully acknowledge the study team at all involved hospitals for their assistance of this study. Siriraj hospital: Mrs. Surangkana Samanloh; Taksin hospital: Mrs. Duangruethai Jankiew, Dr. Kittipong Sae-lao and Ms. Potjana Chularat; Vachira Phuket hospital: Ms. Somruedee Chatchawej and Dr. Busaya Santisant; Lerdsin hospital: Ms. Pranee Watagulsin; Central hospital: Ms. Nattasin Pimhom and Ms. Pornsikan Charutchoksawat. Additionally, we thank Katie Oakley, PhD, from Edanz Group (<https://en-author-services.edanzgroup.com/>) for editing a draft of this manuscript.

Financial support. This research project was supported by Siriraj Research Fund, Grant number (IO) R016333038, Faculty of Medicine Siriraj Hospital, Mahidol University.

Potential conflicts of interest. The authors have no conflicts of interest to declare.

Authors' contributions. All authors made substantial contribution to the interpretation and analysis of data. The corresponding author had full access to the data and responsibility for the decision to submit the manuscript for publication.

References

1. World Health Organization. Coronavirus disease (COVID-19) Situation Report – 139. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.pdf?sfvrsn=79dc6d08_2 (accessed June 8, 2020).
2. Srinivas P, Sacha G, Koval C. Antivirals for COVID-19. *Cleve Clin J Med* 2020.
3. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* 2017; **93**: 449-63.
4. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. *Antimicrob Agents Chemother* 2005; **49**: 981-6.
5. Bai CQ, Mu JS, Kargbo D et al. Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. *Clin Infect Dis* 2016; **63**: 1288-94.
6. Du YX, Chen XP. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. *Clin Pharmacol Ther* 2020.
7. Cai Q, Yang M, Liu D et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering (Beijing)* 2020.
8. Chang Chen, Jianying Huang, Zhenshun Cheng et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv preprint* <https://doi.org/10.1101/2020031720037432> [e-pub ahead of print] 2020.
9. Wang Y, Fan G, Salam A et al. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. *J Infect Dis* 2020; **221**: 1688-98.
10. Nguyen TH, Guedj J, Anglaret X et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. *PLoS Negl Trop Dis* 2017; **11**: e0005389.
11. Royal College of Physicians National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party London: RCP, 2017.

- 353 12. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 -
354 Preliminary Report. *N Engl J Med* 2020.
- 355 13. Goyal P, Choi JJ, Pinheiro LC et al. Clinical Characteristics of Covid-19 in New York City. *N*
356 *Engl J Med* 2020; **382**: 2372-4.
- 357 14. Grasselli G, Zangrillo A, Zanella A et al. Baseline Characteristics and Outcomes of 1591
358 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020.
- 359 15. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel
360 coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506.

361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382

383 **Table 1.** Baseline demographics and characteristics of all patients.

Variables	All (n = 63)	Day 7 Clinical improvement		p-value
		Yes (n = 42)	No (n = 21)	
Age, median (range), year	48 (22–85)	47 (23–72)	59 (22–85)	0.02
Male sex	39 (61.9%)	25 (59.5%)	14 (66.7%)	0.78
Body weight, median (range), kg	69 (45–125)	68 (51–125)	76 (45–120)	0.08
Body mass index median (range), kg/m ²	26.1 (19.0–43.8)	25.0 (19.0–43.8)	27.9 (20.8–39.2)	0.04
Duration between, median (range), day				
Symptom onset and admission date	6 (0–28)	6 (0–28)	8 (0–15)	0.08
Admission date and Day-1 of favipiravir therapy	1 (-8–10)	1 (-3–10)	0 (-8–5)	0.002
Symptom onset and Day-1 of favipiravir therapy	8 (0–28)	8 (2–28)	8 (0–11)	0.60
Exposure risk				
Contact with confirmed COVID-19 cases	26 (41.3%)	19 (45.2%)	7 (33.3%)	0.42
Travel abroad	7 (11.1%)	5 (11.2%)	2 (9.5%)	1.00
Contact with a foreigner	11 (17.5%)	8 (19.1%)	3 (14.3%)	0.74
Travel to a local area with clustered cases	38 (60.3%)	28 (66.7%)	10 (47.6%)	0.18
Underlying diseases				
Heart disease and hypertension	9 (14.3%)	7 (16.7%)	2 (9.5%)	0.71
Diabetes mellitus	17 (27.0%)	11 (26.2%)	6 (28.6%)	1.00
Chronic lung disease	4 (6.4%)	2 (7.1%)	1 (4.8%)	1.00
Chronic kidney disease	4 (6.4%)	3 (7.1%)	1 (4.8%)	1.00
Chronic liver disease	3 (4.8%)	3 (7.1%)	0 (0%)	0.55
Solid cancer	4 (6.4%)	2 (7.1%)	1 (4.8%)	1.00
Others	4 (6.4%)	2 (7.1%)	2 (9.5%)	0.60
Clinical presentation upon admission				
Fever or body temperature of >37.5 °C	55 (87.3%)	36 (85.7%)	19 (90.5%)	0.71

Sore throat	44 (69.8%)	27 (64.3%)	17 (81.0%)	0.25
Rhinorrhea	16 (25.4%)	13 (31.0%)	3 (14.3%)	0.22
Cough	47 (74.6%)	30 (71.4%)	17 (81.0%)	0.54
Headache	11 (17.5%)	8 (19.1%)	3 (14.3%)	0.74
Myalgia	17 (27.0%)	12 (28.6%)	5 (23.8%)	0.77
Diarrhea	8 (12.7%)	6 (14.3%)	2 (9.5%)	0.71
Shortness of breath	27 (42.9%)	14 (33.3%)	13 (61.9%)	0.06
Illness severity at the time of favipiravir initiation				
NEWS2 score, median (range)	5 (0–16)	4 (0–11)	5 (0–16)	0.003
Six-point disease severity scale, median (range)	2.5 (1–5)	2 (1–4)	3 (2–5)	<0.001
1 – No O ₂ -supplementation with O ₂ -saturation of >94%	4 (6.4%)	4 (6.4%)	0 (0)	<0.001
2 – No O ₂ -supplementation with O ₂ -saturation of ≤94%	23 (36.4%)	21 (50.0%)	2 (9.5%)	
3 –Requiring O ₂ -supplementation	28 (44.4%)	16 (40.1%)	12 (57.1%)	
4 –Requiring high-flow O ₂ -supplementation or non-invasive mechanical ventilation	4 (6.4%)	1 (2.4%)	3 (14.3%)	
5 –Requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation	4 (6.4%)	0 (0%)	4 (19.1%)	
Baseline laboratory values*				
Hemoglobin, median (range), (mg/dl)	14.0 (8.0–18.0)	14.0 (9.0–17.0)	13.5 (8.0–18.0)	0.48
White blood cell count, median (range), (cell/mm ³)	5735 (2910–41300)	5420 (2910–41300)	6810 (3180–15750)	0.03
Serum creatinine, median (range), (mg/dl)	0.9 (0.3–22.9) (n = 58)	0.9 (0.4–22.9) (n = 27)	0.9 (0.33–5.1) (n = 21)	0.67
Serum albumin, median (range), (mg/dl)	4.0 (1.8–4.9) (n = 53)	4.2 (1.8–5.0) (n = 33)	3.5 (2.6–4.1) (n = 20)	0.002
Serum lactate dehydrogenase, median (range), (mg/dl)	404 (145–1094) (n = 30)	382 (145–567) (n = 17)	453 (313–1094) (n = 13)	0.03

Indication of favipiravir therapy				
Abnormal chest imagining only	26 (41.3%)	24 (57.1%)	2 (9.5%)	<0.001
Required O ₂ -supplementation only	3 (4.7%)	2 (4.7%)	1 (4.8%)	
Abnormal chest imaging and required O ₂ -supplementation	34 (54.0%)	16 (38.1%)	18 (85.7%)	
Favipiravir regimen				
Dose per bw, median (range), mg/kg/day				
Loading dose	47.4 (29.1–71.1)	49.2 (29.1–62.7)	45.7 (29.6–71.1)	0.47
Maintenance dose	17.9 (10.9–26.7)	18.5 (10.9–23.5)	17.1 (11.1–26.7)	0.37
Potentially sub-therapeutic dose				
Loading dose of ≤45 MKD	21 (33.3%)	11 (26.2%)	10 (47.6%)	0.10
Maintenance dose of ≤15 MKD	48 (76.2%)	33 (78.6%)	15 (71.4%)	0.55
Duration of therapy, median (range), day	12 (2–17)	11.5 (2–16)	12 (2–17)	0.02
Other medications used**				
Any chloroquine-based agent	62 (98.4%)	41 (97.6%)	21 (100%)	1.00
Hydroxychloroquine	54 (85.7%)	36 (85.7%)	18 (85.7%)	1.00
Chloroquine	14 (22.2%)	8 (19.1%)	6 (28.6%)	0.52
Any protease inhibitor	61 (96.8%)	40 (95.2%)	21 (100,0%)	0.55
Darunavir/ritonavir	51 (81.0%)	35 (83.3%)	16 (76.2%)	0.51
Lopinavir/ritonavir	22 (34.9%)	13 (31.0%)	9 (42.9%)	0.26
Azithromycin	31 (49.2%)	17 (40.5%)	14 (66.7%)	0.06
Steroid	8 (12.7%)	5 (11.9%)	3 (14.3%)	1.00
Tocilizumab	4 (6.4%)	1 (2.4%)	3 (14.3%)	0.10

384 **Note.** *Earliest results of a test obtained within the first 7 days of admission (missing data was
385 replaced by the mean value of the variable)

386 ** Medications used within 2 days before or after the initiation of favipiravir therapy

387

388

389

390 **Table 2.** Hospital course and treatment outcomes

Variables	All patients (n = 63)
Clinical improvement	
Day-7 clinical improvement	42 (66.7%)
Patients who did not require O ₂ -supplementation (n = 27)	25 (92.6%)
Patients who required O ₂ -supplementation (n = 36)	17 (47.2%)
Day-14 clinical improvement	54 (85.7%)
Patients who did not require O ₂ -supplementation (n = 27)	27 (100.0%)
Patients who required O ₂ -supplementation (n = 36)	27 (75.0%)
Day-28 clinical improvement	57 (90.5%)
Patients who did not require O ₂ -supplementation (n = 27)	27 (100.0%)
Patients who required O ₂ -supplementation (n = 36)	30 (83.3%)
ICU duration, median (range), day	0 (0–46)
Required invasive mechanical ventilation or ECMO* during hospitalization	8 (12.7%)
Before initiation of favipiravir	4 (6.3%)
After initiation of favipiravir	4 (6.3%)
14-day mortality rate	1 (1.6%)
28-day mortality rate	3 (4.8%)
In-hospital mortality rate	5 (7.9%)
Length of hospital stay, median (range), day	15 (2–47)
Adverse drug reactions	39 (61.9%)
Diarrhea	34 (54.0%)
Hepatitis	4 (6.4%)
QT interval prolongation	4 (6.4%)
Nausea and vomit	5 (7.9%)
Superimposed bacterial infection	8 (12.7%)

391 **Note.** *ECMO: extracorporeal membrane oxygenation

Table 3. Factors associated with Day-7 clinical improvement

Variables	Unadjusted Odd Ratio [95%CI ; <i>p</i> -value]	Adjusted Odd Ratio [95%CI ; <i>p</i> -value]
Age, year	0.95 [0.92 -0.99; <i>p</i> =0.02]	0.94 [0.89–0.99; <i>p</i> =0.04]
Baseline NEWS2 score	0.77 [0.65-0.92; <i>p</i> =0.004]	0.64 [0.47 – 0.88; <i>p</i> =0.006]
Low loading dose of favipiravir	0.39 [0.13-1.17; <i>p</i> =0.09]	0.04 [0.005–0.41; <i>p</i> =0.006]

Figure 1. Rate of clinical improvement on Day 7, Day 14, and Day 28 of favipiravir therapy, stratified by the requirement for O₂-supplementation.